Evidence map›Paper›PMID 30397888›Full record

ArticleDoklady. Biochemistry and biophysics2018

Polyprenyl Phosphates Induce a High Humoral and Cellular Response to Immunization with Recombinant Proteins of the Replicative Complex of the Hepatitis C Virus.

O V Masalova, E I Lesnova, A A Onishchuk, A M Ivanova, E V Gerasimova, A V Ivanov, A N Narovlyansky, A V Sanin, A V Pronin, A A Kushch

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

O V MasalovaGamaleya National Research Centre of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia. ol.mas@mail.ru.
E I LesnovaGamaleya National Research Centre of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia.
A A OnishchukRUDN, Moscow, 117198, Russia.
A M IvanovaGamaleya National Research Centre of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia.
E V GerasimovaGamaleya National Research Centre of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia.
A V IvanovGamaleya National Research Centre of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia.
A N NarovlyanskyGamaleya National Research Centre of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia.
A V SaninGamaleya National Research Centre of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia.
A V ProninGamaleya National Research Centre of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia.
A A KushchGamaleya National Research Centre of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia.
Ministry of Health of the Russian Federation · RURussian New University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for new adjuvants remains the critical task for the creation of hepatitis C vaccines due to the weak immunogenicity of biotechnological products. When immunizing mice with the recombinant proteins NS3 and NS5B of the hepatitis C virus (HCV), the adjuvant activity of three immunomodulators was compared. Phosprenyl® on the basis of polyprenyl phosphate (PPP), chemically synthesized analogue of the bacterial cell wall glucosaminyl muramyl dipeptide (GMDP), and IFN-α recombinant protein were tested. GMDP increased the activity of IgG1 antibodies 4-6 times but did not stimulate the production of IFN-γ; IFN-α has not shown any adjuvant properties. The introduction of recombinant HCV proteins together with PPP in low doses increased the activity of IgG2a isotype antibodies 4-7 times and increased IFN-γ secretion 3 times. Thus, it was first shown that PPP polarizes the immune response to Th1-type and is a promising adjuvant for the development of a vaccine against hepatitis C.

Indexed as

Adjuvants, ImmunologicAnimalsHepacivirusImmunity, CellularImmunity, HumoralImmunoglobulin GImmunologic FactorsMicePolyisoprenyl PhosphatesRecombinant ProteinsVaccinesVirus ReplicationAdjuvants, ImmunologicImmunoglobulin GImmunologic FactorsPolyisoprenyl Phosphatespolyprenyl monophosphateRecombinant ProteinsVaccines

Identifiers

PMID30397888
OpenAlexW2899696959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.